TY - JOUR
T1 - Enhanced reactive oxygen species metabolism of airspace cells and airway inflammation follow antigen challenge in human asthma
AU - Calhoun, William J.
AU - Bush, Robert K.
AU - Salisbury, Steven M.
AU - Stevens, Carol A.
N1 - Funding Information:
The airway obstruction and inflammation that follow antigen exposure in antigen-sensitive humans is multifactorial, with demonstrated participation of eicosanoids, histamine, and other mast cell products.l3 Although mast cell activation and mediator release are important in this process, other cells also participate. Eosinophils have been demonstrated both in tissue 4 and in BAL specimens in subjects with From the Sections of *Pulmonary and Critical Care Medicine, and **Allergy/Immunology, Department of Medicine, University of Wisconsin, Madison, and **Allergy Section, William S. Mid-dleton Veterans Administration Hospital, Madison, Wis. Supported in part by National Heart, Lung, and Blood Institute Clinical Investigator Award K08-01828, American Lung Asso-ciation, Graduate School Research Committee, Medical School Research Committee, and Research and Development Commit-tee, Department of Medicine, University of Wisconsin, Madison, Wis., and Veterans Administration Merit Review Funds. Received for publication Sept. 29, 1989. Revised Jan. 11, 1990. Accepted for publication April 7, 1990. Reprint requests: William J. Calhoun, MD, Assistant Professor of Medicine, Section of Pulmonary and Critical Care Medicine, H6/384 CSC, University of Wisconsin, Madison, WI 53792. 1/1/21734
PY - 1990/9
Y1 - 1990/9
N2 - Airflow limitation and airway inflammation follow antigen bronchoprovocation in sensitized individuals. Inflammation likely results from the interplay of several previously demonstrated factors, but the participation and persistance of enhanced reactive oxygen species (ROS) metabolism of airspace cells after antigen challenge have received more limited attention. We studied nine subjects with mild asthma by bronchoalveolar lavage before and 48 (one subject) to 72 (eight subjects) hours after antigen bronchoprovocation and compared airspace cell numbers and types, cell function, and bronchoalveolar lavage fluid protein, albumin, and immunoglobulins. Mild, but significant, airflow limitation persisted at the time of the second lavage. Eosinophil influx was a notable component of the increased airspace cells in postchallenge lavages. Airspace cells demonstrated significantly enhanced ROS metabolism, and total protein, albumin, and IgM levels were higher in postchallenge lavage specimens. Antigen bronchial challenge produces airspace inflammation, which may develop, in part, as a consequence of enhanced ROS metabolism of airspace cells.
AB - Airflow limitation and airway inflammation follow antigen bronchoprovocation in sensitized individuals. Inflammation likely results from the interplay of several previously demonstrated factors, but the participation and persistance of enhanced reactive oxygen species (ROS) metabolism of airspace cells after antigen challenge have received more limited attention. We studied nine subjects with mild asthma by bronchoalveolar lavage before and 48 (one subject) to 72 (eight subjects) hours after antigen bronchoprovocation and compared airspace cell numbers and types, cell function, and bronchoalveolar lavage fluid protein, albumin, and immunoglobulins. Mild, but significant, airflow limitation persisted at the time of the second lavage. Eosinophil influx was a notable component of the increased airspace cells in postchallenge lavages. Airspace cells demonstrated significantly enhanced ROS metabolism, and total protein, albumin, and IgM levels were higher in postchallenge lavage specimens. Antigen bronchial challenge produces airspace inflammation, which may develop, in part, as a consequence of enhanced ROS metabolism of airspace cells.
UR - http://www.scopus.com/inward/record.url?scp=0024989095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024989095&partnerID=8YFLogxK
U2 - 10.1016/S0091-6749(05)80092-2
DO - 10.1016/S0091-6749(05)80092-2
M3 - Article
C2 - 2212406
AN - SCOPUS:0024989095
SN - 0091-6749
VL - 86
SP - 306
EP - 313
JO - The Journal of Allergy and Clinical Immunology
JF - The Journal of Allergy and Clinical Immunology
IS - 3 PART 1
ER -